A PHASE I STUDY OF LY3076226, A FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED OR METASTATIC CANCER

Registry ID

I7O-MC-JOBA(A)

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ELI LILLY CANADA INC

Start date

2017-10-04

Last update

2016-02-11

Conditions

• ADVANCED CANCERS

Related clinical trials

• A PHASE 1, FIRST IN HUMAN STUDY OF TORL-4-500 IN PATIENTS WITH ADVANCED CANCER
• PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE-3 BETA (GSK-3B) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY, IN PATIENTS WITH REFRACTORY HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS
• PSILOCYBIN-ASSISTED EXISTENTIAL, ATTACHMENT AND RELATIONAL (PEARL) THERAPY FOR PATIENTS WITH ADVANCED CANCER: A PHASE II OPEN-LABEL TRIAL
• A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF CC-95251, A MONOCLONAL ANTIBODY DIRECTED AGAINST SIRP¿, ALONE AND IN COMBINATION WITH CETUXIMAB IN SUBJECTS WITH ADVANCED SOLID CANCERS
• "A PHASE 1/2A STUDY OF BMS-986253 IN COMBINATION WITH NIVOLUMAB IN ADVANCED CANCERS."
• A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED RARE TUMOURS

View on source registry